IP Library Granted Patent US 7,417,036
Granted Patent B2
US 7,417,036 · App. 10/534,602 · Granted Aug 26, 2008

Crystal form of adefovir dipivoxil and its preparation

Assignee: Tianjin Kinsly Pharmaceutical Co. Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,417,036
App. No.
10/534,602
Granted
Aug 26, 2008
Kind
B2
Abstract

A new crystal form of adefovir dipivoxil {9-[2-[bis(pivaloyloxy)-methoxy]-phosphinyl]-methoxyl]-ethyl]-adenime} and its composition is disclosed, as is a method to prepare the crystal comprising placing adefovir dipivoxil in a round bottom flask, adding organic solvent and dissolivng adefovir dipivoxil ultrasonically to form and adefovir dipivoxil solution, and spray drying the adefovir dipivoxil solution.

Claims (11)

1. A crystalline adefovir dipivoxil, characterized in that it has characteristic peaks expressed in terms of 2θ at about 3.60, about 7.28, about 15.08, about 17.24, about 17.96, about 20.12, and about 22.24 in X-ray powder diffraction pattern with Cu target radiation, an endothermic peak at about 94.5° C. in DSC thermogram, a melting point at 94° C. to 95° C., and peaks at about 3320 cm −1 , about 3160 cm −1 , about 2975 cm −1 , about 1755 cm −1 , and about 1650 cm −1 in Fourier Transform Infrared Spectrum.

2. A composition comprising the crystalline adefovir dipivoxil of claim 1 and one or more pharmaceutically acceptable carriers or excipients.

3. The composition of claim 2 in unit dosage form wherein each dosage unit contains 100-400 mg crystalline adefovir dipivoxil.

4. The composition of claim 2 in unit dosage form wherein each dosage unit contains 1-80 mg crystalline adefovir dipivoxil.

5. A process for preparing the crysyalline adefovir dipivoxil of claim 1 , comprising:

a. Placing adefovir dipivoxildipivoxil in a round bottom flask;

b. Adding organic solvent and dissolving adefovir dipivoxil ultrasonically to form an adefovir dipivoxil solution;

c. Spray drying the adefovir dipivoxil solution formed by step b to form a powder; and

d. Collecting the powder to obtain the crystalline adefovir dipivoxil.

6. The process of claim 5 , wherein said organic solvent of step (b) is selected from the group consisting of anhydrous ethanol, methanol, acetone, acetonitrile/di-n-butyl ether, and methylene chloride and the formed adefovir dipivoxil solution has an adefovir dipivoxil concentration of 100-300 g/L; in step (c),the inlet air temperature is set at 85-100° C., the measured inlet air temperature is 85-100° C.; the measured outlet air temperature is 50-75° C.; pump output efficiency is 5-15step (c),the inlet air temperature is set at 85-100° C., the emasured inlet air temperature is 5-15%; air pump output efficiency is 70%-95%; and the rate of airflow of the air compressor is at 600 L/L-800 L/L.

7. The process of claim 5 , wherein said organic solvent of step (b) is ethanol and said adefovir dipivoxil solution has an adefovir dipivoxil concentration of 200 g/L; in step (c), said inlet air temperature is set at 95° C., the measured inlet air temperature is 95° C.; the measured outlet air temperature is 60° C. ;pump output efficiency is 8%; air pump output efficiency is 85%; and the rate of airflow of the air compressor is at 700 L/L.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2016
From: TIANJIN DISHILI INVESTMENT HOLDING GROUP, LIMITED
To: JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.
Reel/Frame 039972/0739 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 023720 FRAME 0460. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE NAME SHOULD BE TIANJIN DISHILI INVESTMENT HOLDING GROUP, LIMITED. Recorded Jan 13, 2010
From: TIANJIN KINSLY PHARMACEUTICAL CO. LTD.
To: TIANJIN DISHILI INVESTMENT HOLDING GROUP, LIMITED
Reel/Frame 023776/0735 →
CHANGE OF NAME Recorded Dec 31, 2009
From: TIANJIN KINSLY PHARMACEUTICAL CO. LTD.
To: TIANJIN DISHILI INVESTMENT GROUP, LIMITED
Reel/Frame 023720/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2005
From: WANG, GUOCHENG; LU, XINBO; LIU, QINXUAN; TANG, YU; YANG, LIPING
To: TIANJIN KINSLY PHARMACEUTICAL CO. LTD.
Reel/Frame 016319/0593 →
Priority Claims (1)
CN 02 1 48923 · Nov 12, 2002 · national
Continuity (1)
Related Publication 20060025384A1 · Feb 2, 2006